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Abstract
Background. The prevalence of albuminuria is known to
be higher in hypertensive compared to normotensive non-
diabetic patients. In addition, systolic blood pressure
(BP) is found to be an independent risk factor for
albuminuria in type 2 diabetes mellitus (T2DM). Based
on these findings, the prevalence of albuminuria is ex-
pected to be higher in T2DM with hypertension relative
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to T2DM without hypertension, but it has been largely
unexplored.
Methods. Prevalence rates of microalbuminuria, macroal-
buminuria and renal insufficiency (RI) were investigated
among 3738 hypertensive T2DM patients from 350 nation-
wide primary care clinics. Independent factors associated
with albuminuria and RI were also characterized.
Results. Clinical and laboratory data of 3712 patients
were included in the analysis. BP was controlled in only
1164 patients (31.4%). There were 2595 normoalbumi-
nuric patients (70.6%), and microalbuminuria and mac-
roalbuminuria were present in 850 (23.1%) and 230
(6.3%), respectively. The prevalence of RI was 32.1%
based on estimated glomerular filtration rate (eGFR) by
Modification of Diet in Renal Disease formula. Systolic
BP correlated significantly with the natural logarithmic
values of urinary albumin-to-creatinine ratio (ACR)
(R ¼ 0.16, P < 0.0001). Multivariate logistic regression
analysis revealed that male sex, the duration of diabetes,
systolic BP, glycated hemoglobin and eGFR were sig-
nificant independent factors associated with the presence
of albuminuria, while advanced age, female sex, the du-
ration of diabetes and urinary ACR were significant in-
dependent risk factors for RI.
Conclusions. A significant proportion of T2DM patients
with hypertension had albuminuria and RI, and the dura-
tion of diabetes mellitus rather than the duration of hyper-
tension was a significant independent factor associated
with albuminuria and RI.
Keywords: albuminuria; diabetic nephropathy; hypertension; renal
insufficiency; type 2 diabetes
Introduction
Recently, the number of patients with diabetes and/or
hypertension has strikingly increased in most countries.
Moreover, since diabetes and hypertension are well-known
risk factors for cardiovascular mortality in not only the
general population but also specific groups of patients
[1, 2], they have become common serious problems
throughout the world. Accumulating evidence has also
shown that there is a close relationship between diabetes
and hypertension. The prevalence of hypertension in
patients with type 2 diabetes (T2DM) is known to be
1.5–3 times higher than in the age-matched nondiabetic
population [3, 4]. In the other direction, patients with hyper-
tension are at a two to three times higher risk for developing
diabetes than those with normal blood pressure (BP) [5].
Diabetic nephropathy is the leading cause of end-stage
renal disease (ESRD) worldwide [6]. Since early detection
of renal involvement in diabetic patients is a critical issue in
terms of delaying the progression of renal disease, several
markers have been used for screening. Proteinuria has been
known for a long time as an independent significant risk
factor for ESRD and cardiovascular disease in diabetic pa-
tients [7, 8]. However, the focus has moved recently to much
earlier stages in renal disease as established by the presence
of microalbuminuria. Microalbuminuria is not only estab-
lished as a significant predictor for the development of overt
diabetic nephropathy but is also associated with increased car-
diovascular morbidity and mortality risk in both type 1 and
type 2 diabetes [9, 10]. The prevalence rate of microalbumi-
nuria is also known to be~2-fold higher in nondiabetic patients
with hypertension [11]. In addition, systolic BP is found to be
an independent risk factor for microalbuminuria in patients
with T2DM [12]. Based on these findings, the prevalence of
microalbuminuria is expected to be higher in T2DM patients
with hypertension compared to those with T2DM or hyper-
tension alone, but it has been largely unexplored.
Numerous studies have clearly demonstrated that strict BP
control is more beneficial in diabetic than in nondiabetic
hypertensive patients [13]. As a result, recently released
guidelines set the target level of BP <130/80 mmHg in
diabetic patients with hypertension [14]. This indicates that
a more aggressive antihypertensive treatment is needed in
diabetic hypertensive patients. Nevertheless, previous stud-
ies have found that BP control rates in these patients are
lower compared to nondiabetic patients with hypertension
[15, 16], and little is known on the difference in BP control
rates according to the stages of diabetic nephropathy and/or
the stages of chronic kidney disease (CKD). In addition, the
relationship between BP control and albuminuria or renal
insufficiency (RI) has not been extensively investigated in
primary care diabetic patients with hypertension.
Therefore, we performed a nationwide cross-sectional
primary care clinic-based study on T2DM patients with
hypertension to investigate (i) the prevalence of microalbu-
minuria and macroalbuminuria, (ii) the frequency of RI,
(iii) the relationship between BP control and albuminuria
and (iv) the relationship between BP control and RI.
Materials and methods
Study design and population
The Korean Epidemiology Study on Hypertension III (KEY III study)
was a nationwide, cross-sectional primary care unit-based study.
Random selection of nationwide primary care physicians based on the
number of residents of each city or province was performed, and survey
letters were sent to the selected 350 primary care clinics. Of the invited
physicians, 300 physicians in 292 clinics agreed to participate in this study
(85.7%).
The eligibility criteria were patients aged >18 years with T2DM and
hypertension. Subjects were considered to have diabetes if they were
receiving insulin or oral hypoglycemic agents or if fasting blood glucose
levels >126 mg/dL. Hypertension was defined based on the patient med-
ical record or if the patient was taking antihypertensive medications. Pa-
tients with type 1 diabetes, pregnancy, acute fever, significant bacteriuria
or hematuria, or previously diagnosed nondiabetic glomerular disease, or
patients who performed excessive exercise within 24 h were excluded.
Informed consent was obtained from all subjects.
Measurements
All subjects were asked to complete a questionnaire to collect information
on demography, lifestyle data and family history of hypertension and
cardiovascular disease. Anthropometrical data, medical history and anti-
hypertensive medication were also recorded by the primary physician.
BP was measured by the physician using a standard electronic sphyg-
momanometer (MX3; Omron Co. Ltd, Dalian, China). Measurement was
performed on the arm of the subject supported at the heart level with an
appropriate cuff after ~10 min of rest in the sitting position. The average of
two consecutive measurements with a 5-min interval was used for analysis.
Morning spot urine and blood samples were sent to the core laboratory
(Green Cross Reference Laboratory, Seoul, Korea) for urinary albumin-to-
creatinine ratio (ACR), serum creatinine and glycated hemoglobin
(HbA1C) level measurements. Urinary albumin concentrations were
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determined by a turbidimetric immunoassay, and plasma and urine crea-
tinine levels by kinetic colorimetric assay using the Jaffe method. HbA1C
was measured by high-performance liquid chromatography.
Microalbuminuria was defined as ACR of 30–299 mg/g and macroalbu-
minuria as ACR >300 mg/g [17]. We used the Modification of Diet in
Renal Disease (MDRD) formula [18] to calculate the estimated glomerular
filtration rate (eGFR) (mL/min/1.73m2). The stages of CKD were defined
according to the American National Kidney Foundation [19]: Stage 1, eGFR
90; Stage 2, eGFR 60–89; Stage 3, eGFR 30–59; Stage 4, 15–29 and
Stage 5, eGFR<15 or dialysis. CKD of Stage 3 or higher was defined as RI.
Statistical analysis
All values are expressed as means  SDs or percentages. Statistical analyses
were performed using SAS (version 9.1; SAS Institute, Cary, NC). Results
were analyzed using analysis of variance (ANOVA), Student’s t-test or chi-
square test for comparisons. Significant differences found by ANOVA were
further confirmed by the Student’s t-test with the Bonferroni correction. The
correlations between the natural logarithmic values of urinary ACR or eGFR
and clinical and laboratory parameters were determined by Pearson’s corre-
lation analysis and independent factors associated with the presence of albu-
minuria or RI were identified by multivariate logistic regression analysis. P-
values <0.05 were considered to be statistically significant.
Results
Demographic characteristics
Among the 3738 recruited cases, 26 patients were ex-
cluded: 12 patients did not meet the inclusion criteria and
14 patients with missing data. Therefore, a total of 3712
patients were included in the analysis.
The mean age of the patients was 62.0  10.7 years, and
1677 (45.2%) were male. The mean durations of diabetes
and hypertension were 7.0  5.9 and 7.7  6.0 years,
respectively, and the mean BP was 130.5  13.5/78.3 
9.1 mmHg. BP was controlled (<130/80 mmHg) at the
time of visit in only 1164 patients (31.4%), although the
primary care physicians considered 93.4% of the subjects
had a well-controlled BP (Table 1).
Among the 3675 patients with available urinary ACR
results, 2595 patients (70.6%) were normoalbuminuric,
and microalbuminuria and macroalbuminuria were present
in 850 patients (23.1%) and 230 patients (6.3%), respec-
tively. The prevalence of RI was 32.1% (Table 2).
Relationship between BP control and albuminuria
Urinary ACR was significantly lower in patients with con-
trolled hypertension compared to those with uncontrolled hy-
pertension (59.6  178.7 versus 81.4  210.7 mg/g,
P ¼ 0.0013).
Relationship between BP control and RI
There was a significant difference in eGFR between pa-
tients with and without controlled hypertension (68.6 
17.9 versus 66.8  16.2 mL/min/1.73m2, P ¼ 0.0026).
Factors associated with albuminuria
Pearson’s correlation analysis revealed that the duration of
diabetes (R ¼ 0.20, P < 0.0001), systolic BP (R ¼ 0.16,
P < 0.0001), HbA1C levels (R ¼ 0.24, P < 0.0001) and
eGFR (R ¼ 0.22, P < 0.0001) correlated significantly
with the natural logarithmic values of urinary ACR.
On the other hand, when the patients were divided into the
normo-, micro- and macroalbuminuric groups there were sig-
nificant differences in the duration of diabetes and hy-
pertension, the presence of diabetic complications, systolic
and diastolic BP, the proportion of patients with controlled
hypertension, patients receiving renin-angiotensin system
blockades or calcium channel blockers, HbA1C levels, urinary
ACR, serum creatinine concentrations, eGFR and the propor-
tion of patients with RI among the three groups (Table 3).
Multivariate logistic regression analysis revealed that
the duration of diabetes [odds ratio (OR) ¼ 1.04, 95%
confidence interval (CI) ¼ 1.02–1.05, P < 0.0001],
the presence of diabetic complications (OR ¼ 1.54,
95% CI ¼ 1.29–1.85, P < 0.0001), systolic BP (OR ¼
1.02, 95% CI ¼ 1.01–1.03, P < 0.0001), HbA1C
(OR ¼ 1.34, 95% CI ¼ 1.26–1.41, P < 0.0001) and eGFR
(OR ¼ 0.98, 95% CI ¼ 0.97–0.98, P < 0.0001) were sig-
nificant independent factors associated with the presence of
microalbuminuria or macroalbuminuria (Table 4).
Further multivariate logistic regression analysis was
performed with albuminuric patients to identify indepen-
dent differentiating factors of macroalbuminuria from mi-
croalbuminuria. As a result, age (OR ¼ 0.96, 95% CI ¼
Table 1. Demographic characteristics of patients (N ¼ 3712)a
Mean 6 SD or N (%)
Age (years) 62.0 6 10.7
Male:female 1677:2035
Body mass index (kg/m2) 24.8 6 3.2
Duration of diabetes (years) 7.0 6 5.9
Duration of hypertension (years) 7.7 6 6.0
Family history
Diabetes 1724 (46.4)
Hypertension 1447 (39.2)
Smoking
Smoker 724 (19.6)
Ex-smoker 703 (19.1)
Nonsmoker 2260 (61.3)
Drinker 1394 (37.8)
Diabetic complications (yes) 894 (24.1)
Systolic BP (mmHg) 130.5 6 13.5
Diastolic BP (mmHg) 78.3 6 9.1
Antihypertensive drugs
ARB or ACEi 2841 (76.5)
CCB 1728 (46.6)
Beta-blocker 417 (11.2)
Diuretics 1600 (43.1)
Others 204 (5.5)
BP control
Controlled 1164 (31.4)
Uncontrolled 2548 (68.6)
aACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin recep-
tor blocker; CCB, calcium channel blocker.
Table 2. Laboratory findings of patients
Mean 6 SD or n (%)
Glucose (mg/dL) 175.3 6 48.3
HbA1C (%) 7.09 6 1.36
Urinary ACR (mg/g) 74.6 6 201.4
Serum creatinine (mg/dL) 1.10 6 0.58
eGFR (mL/min/1.73m2) 68.0 6 17.4
Albuminuria
Normoalbuminuria 2595 (70.6)
Microalbuminuria 850 (23.1)
Macroalbuminuria 230 (6.3)
RI 1188 (32.1)
Diabetic nephropathy in hypertensive diabetic patients 3251
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0.94–0.98, P < 0.0001), male sex (OR ¼ 0.61, 95% CI ¼
0.43–0.84, P ¼ 0.0033), systolic BP (OR ¼ 1.02, 95%
CI ¼ 1.01–1.04, P < 0.0001), HbA1C (OR ¼ 1.13, 95%
CI ¼ 1.02–1.25, P ¼ 0.0191) and eGFR (OR ¼ 0.96,
95% CI ¼ 0.95–0.97, P < 0.0001) were significantly
associated with the presence of macroalbuminuria.
Factors associated with RI
Pearson’s correlation analysis revealed that age (R ¼ 0.32,
P < 0.0001), the duration of diabetes (R ¼ 0.20, P <
0.0001), the duration of hypertension (R ¼ 0.17, P <
0.0001) and the natural logarithmic values of urinary ACR
(R ¼ 0.25, P < 0.0001) correlated significantly with the
values of eGFR.
On the other hand, when the patients were divided into two
groups based on eGFR by the MDRD formula: Group 1 con-
sisted of patients with CKD of Stage 1 or 2, Group 2 was
patients with RI, the mean age and the proportion of female
were significantly higher in patients with RI. The duration of
diabetes and hypertension was significantly longer, diastolic
BP was significantly lower and patients with controlled hyper-
tension were significantly more prevalent in the RI group.
HbA1C levels and urinary ACR were significantly higher,
and the proportion of patients with micro- or macroalbuminu-
ria was significantly higher in Group 2 patients (Table 5).
Multivariate logistic regression analysis revealed that age
(OR ¼ 1.07, 95% CI ¼ 1.06–1.08, P < 0.0001), female sex
(OR ¼ 0.34, 95% CI¼ 0.27–0.43, P< 0.0001), the duration
of diabetes (OR ¼ 1.03, 95% CI ¼ 1.01–1.04, P ¼ 0.0012),
the presence of diabetic complications (OR ¼ 1.37, 95% CI
¼ 1.13–1.66, P ¼ 0.0116) and urinary ACR (OR ¼ 1.00,
95% CI ¼ 1.00–1.00, P < 0.0001) were significant inde-
pendent risk factors for RI (Table 6).
Discussion
The Korean Epidemiology Study on Hypertension III
(KEY III study), which included the largest number of only
hypertensive T2DM patients managed by primary care
physicians in a single nation, was designed to explore the
prevalence of diabetic nephropathy and to identify the in-
dependent factors associated with diabetic nephropathy in
these patients. The results of this study reveal that a sig-
nificant proportion of T2DM patients with hypertension
Table 3. Comparison between patients with normo-, micro- and macroalbuminuriaa
Normo-
(N ¼ 2595)
Micro-
(N ¼ 850)
Macro-
(N ¼ 230) P-value
Age (years) 61.8 6 10.5 62.7 6 11.3 61.1 6 10.4 0.0468
Sex 0.4743
Male 1156 (44.5) 384 (45.2) 112 (48.7)
Female 1439 (55.5) 466 (54.8) 118 (51.3)
Body mass index (kg/m2) 24.8 6 3.2 24.7 6 3.2 24.6 6 2.9 0.4429
Duration of diabetes (years) 6.4 6 5.4 8.1 6 6.6 10.1 6 7.5 <0.0001
Duration of hypertension (years) 7.4 6 5.8 8.2 6 6.3 9.3 6 7.0 <0.0001
Diabetic complications 524 (20.2) 244 (28.7) 113 (49.3) <0.0001
Systolic BP (mmHg) 129.3 6 12.8 132.3 6 14.1 136.6 6 15.4 <0.0001
Diastolic BP (mmHg) 77.8 6 8.7 78.9 6 9.7 80.8 6 10.3 <0.0001
Antihypertensive drugs
ARB or ACEi 1964 (75.7) 645 (75.9) 216 (93.9) 0.0256
CCB 1171 (45.1) 435 (51.2) 107 (46.5) 0.0090
Beta-blocker 291 (11.2) 90 (10.6) 34 (14.8) 0.1985
Diuretics 1138 (43.9) 337 (39.6) 104 (45.2) 0.1408
Others 137 (5.3) 45 (5.3) 20 (8.7) 0.0892
BP control <0.0001
Controlled 880 (33.9) 223 (26.2) 50 (21.7)
Uncontrolled 1715 (66.1) 627 (73.8) 180 (78.3)
HbA1C (%) 6.91 6 1.22 7.47 6 1.48 7.74 6 1.71 <0.0001
Urinary ACR (mg/g) 12.6 6 6.60 87.5 6 61.4 725.4 6 408.5 <0.0001
Serum creatinine (mg/dL) 1.05 6 0.50 1.09 6 0.33 1.65 6 1.25 <0.0001
eGFR (mL/min/1.73m2) 69.8 6 15.9 67.0 6 17.9 53.2 6 23.2 <0.0001
CKD stage <0.0001
Stage 1 or 2 1863 (71.8) 538 (63.3) 86 (37.4)
Stages 3–5 732 (28.2) 312 (36.7) 144 (62.6)
aACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, cal-
cium channel blocker.
Table 4. Factors associated with the presence of micro-/
macroalbuminuriaa
Factor OR (95% CI) P-value
Age (years) 0.99 (0.98–1.00) 0.0309
Sex (male versus female) 1.31 (1.11–1.54) 0.0024
Duration of diabetes (years) 1.04 (1.02–1.05) <0.0001
Duration of hypertension (years) 1.00 (0.98–1.01) 0.5407
Diabetic complications (yes versus no) 1.54 (1.29–1.85) <0.0001
Systolic BP (mmHg) 1.02 (1.01–1.03) <0.0001
Diastolic BP (mmHg) 1.01 (1.00–1.02) 0.7344
Usage of ARB or ACEi (yes versus no) 0.99 (0.82–1.19) 0.2634
Usage of CCB (yes versus no) 1.27 (1.08–1.50) 0.0039
HbA1C (%) 1.34 (1.26–1.41) <0.0001
eGFR (mL/min/1.73m2) 0.98 (0.97–0.98) <0.0001
aARB, angiotensin receptor blocker; ACEi, angiotensin-converting en-
zyme inhibitor; CCB, calcium channel blocker.
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(~30%) had albuminuria (micro or macro) and/or RI. In
addition, the duration of diabetes, systolic BP, HbA1C
and the presence of RI were significant independent factors
associated with the presence of albuminuria, while age, the
duration of diabetes and urinary ACR were significant in-
dependent risk factors for RI.
Microalbuminuria is not only the earliest manifestation
of diabetic nephropathy but is also a significant risk factor
for the progression of nephropathy in diabetic patients
[20]. Accumulating evidence has also shown that micro-
albuminuria is closely associated with cardiovascular mor-
bidity or mortality in patients with diabetes [9, 10]. In
addition, reduction of urinary albumin excretion by using
inhibitors of the renin-angiotensin system improves the
course of diabetic nephropathy as well as cardiovascular
risks in diabetic patients [21, 22]. Therefore, early detection
and aggressive management of microalbuminuria is vitally
important in diabetic patients. In the same context, the
American Diabetes Association recommends annual
screening for microalbuminuria in patients with diabetes
[17]. However, since microalbuminuria is asymptomatic
and determination of urinary ACR is not invariably per-
formed in primary care clinics in many countries, including
Korea, the prevalence of nephropathy in diabetic patients
cared by primary care physicians may be actually higher
than recognized by patients or doctors. In the present study,
diabetic nephropathy as diagnosed by physician or known
by patient was only 6.1%, but micro- or macroalbuminuria
were actually present in 850 patients (23.1%) and 230 pa-
tients (6.3%), respectively. Bramlage et al. [23] also ob-
served a great discordance between the proportion of
patients with nephropathy diagnosed by physician and by
laboratory results. Even though only 7.3% of 39025 pri-
mary care attendees had nephropathy as diagnosed by the
physician, dipstick test revealed microalbuminuria in 7416
patients (19.0%). Moreover, among diabetic patients, the
proportion of patients with microalbuminuria increased to
33.6%. Based on these findings, a significantly large num-
ber of diabetic patients seem to be underdiagnosed and
undertreated by primary care physicians in many countries
and therefore, an intensive education of patients as well as
general practitioners on microalbuminuria is mandatory to
detect patients at higher cardiovascular risk early and to
aggressively treat microalbuminuria, one of the modifiable
risk factors in diabetic patients. On the other hand, most of
the previous studies including a large number of patients
used semiquantitative dipstick such as Micral-Test II
(Boehringer Mannheim, Mannheim, Germany), Clinitek
50 (Bayer Diagnostic Manufacturing Ltd, Bridgend,
UK) or Multistix 10SG (Bayer Diagnostic Manufacturing
Ltd) for screening of microalbuminuria [23–26]. Even
Table 5. Comparison between patients without and with RI based on eGFRa
RI () (N ¼ 2510) RI (1) (N ¼ 1188) P-value
Age 59.7 6 10.5 66.8 6 9.6 <0.0001
Sex <0.0001
Male 1321 (52.6) 347 (29.2)
Female 1189 (47.4) 841 (70.8)
Body mass index (kg/m2) 24.8 6 3.2 24.7 6 3.2 0.3900
Duration of diabetes (years) 6.3 6 5.3 8.6 6 6.8 <0.0001
Duration of hypertension (years) 7.1 6 5.6 9.0 6 6.6 <0.0001
Diabetic complications 508 (20.3) 384 (32.4) <0.0001
Systolic BP (mmHg) 130.5 6 13.1 130.5 6 14.4 0.9185
Diastolic BP (mmHg) 79.0 6 8.9 76.9 6 9.4 <0.0001
Antihypertensive drugs
ARB or ACEi 1904 (75.9) 918 (77.3) 0.4845
CCB 1167 (46.5) 554 (46.6) 0.9369
Beta blocker 245 (9.8) 170 (14.3) <0.0001
Diuretics 1070 (42.6) 524 (44.1) 0.0280
Others 126 (5.0) 77 (6.5) 0.0684
BP control 0.0456
Controlled 761 (30.3) 399 (33.6)
Uncontrolled 1749 (69.7) 789 (66.4)
HbA1C (%) 7.04 6 1.31 7.21 6 1.45 0.0007
Urinary ACR (mg/g) 50.5 6 142.5 126.2 6 283.0 <0.0001
Serum creatinine (mg/dL) 0.95 6 0.15 1.41 6 0.92 <0.0001
Albuminuria <0.0001
Normoalbuminuria 1863 (74.9) 721 (61.4)
Microalbuminuria 538 (21.6) 309 (26.3)
Macroalbuminuria 86 (3.5) 144 (12.3)
aACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, cal-
cium channel blocker.
Table 6. Factors associated with the presence of RI
Factors OR (95% CI) P-value
Age (years) 1.07 (1.06–1.08) <0.0001
Sex (male versus female) 0.34 (0.27–0.43) <0.0001
Duration of diabetes (years) 1.03 (1.01–1.04) 0.0012
Duration of hypertension (years) 1.00 (0.98–1.01) 0.3838
Diabetic complications (yes versus no) 1.37 (1.13–1.66) 0.0116
Diastolic BP (mmHg) 0.99 (0.99–1.01) 0.2763
Usage of beta blocker (yes versus no) 1.50 (1.17–1.92) 0.0047
Usage of diuretics (yes versus no) 1.06 (0.90–1.24) 0.2646
HbA1C (%) 1.04 (0.97–1.10) 0.4197
Urinary ACR (mg/g) 1.00 (1.00–1.00) <0.0001
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though the sensitivity and specificity of these strips have
been reported to be relatively high [27], they are less accu-
rate compared to direct measurement of urinary albumin
and creatinine concentrations. In this study, therefore, we
directly determined urinary albumin and creatinine concen-
trations to precisely classify >3600 patients into normo-,
micro- or macroalbuminuric patients based on the results of
urinary ACR. Nevertheless, there is a possibility that a few
patients may be classified into an incorrect group. Accord-
ing to the guidelines, the diagnosis of micro- and macro-
albuminuria should be made based on the results of three
urine specimens collected within a 6-month period. How-
ever, since collection of three random urine samples from
the same patients in nationwide primary care clinics was
not easy to perform, a single morning urine sample was
used to determine urinary ACR in the present study. In-
stead, we tried to exclude patients with a potential to have
elevated urinary ACR, such as pregnant patients, patients
with febrile illness or urinary tract infection or patients who
performed excessive exercise within 24 h.
Surprisingly, the proportion of patients with RI was sig-
nificantly higher than that observed by physicians or pa-
tients. Among 3712 patients, 1193 (32.1%) were patients
with CKD of more than Stage 3. Two recent studies also
revealed high incidence of RI in Asian T2DM patients
attending primary care clinics [28, 29]. Pan et al. [28] found
that 23% of 2841 primary care patients with T2DM had RI
and Yokoyama et al. [29] observed that the proportion of
primary care T2DM with RI was 15.3%. Compared to these
two studies, the incidence of renal failure in this study was
somewhat higher, which may be attributed to the presence
of concomitant hypertension. Hypertension was accompa-
nied in 52.0 and 48.4% in the studies by Pan et al. [28] and
Yokoyama et al. [29], respectively, while all subjects of our
study were hypertensive T2DM patients. Taken together, a
significant proportion of T2DM patients in primary care
settings, regardless of the presence of hypertension, have
RI without patients’ or doctors’ recognition, necessitating
close monitoring of the patients’ serum creatinine by their
primary care physicians.
Hypertension per se is associated with higher risk of
cardiovascular and renal diseases [2, 30]. The incidence of
microalbuminuria is also found to be higher in hyperten-
sive patients, even in nondiabetic patients [11]. The re-
sults of the study by Bramlage et al. [23] demonstrated
that even though the frequency rates of microalbuminuria
were comparable among nondiabetic patients with a
BP <120/70, 120/70–130/80 and 130/80–140/90 mmHg,
the rates were increased in cases with BP >140/90 mmHg.
In contrast, the increase in BP was closely related to an
increase in the incidence of microalbuminuria in T2DM
patients over the whole range of BP categories. A
recent Hong Kong study on 492 hypertensive T2DM pa-
tients also showed that the magnitude of systolic BP was
one of the predictive factors for the presence of micro-
albuminuria [31]. On the other hand, MicroAlbuminuria
Prevalence Study (MAPS), the first large multicenter
epidemiological study in Asia to determine the prevalence
of microalbuminuria and macroalbuminuria in 6801 patients
with hypertension and T2DM, revealed that the duration of
hypertension was associated with the degree of albuminuria
on univariate analysis [25]. In the present study, we also
found that systolic BP correlated significantly with urinary
ACR and was a significant independent factor associated
with the presence of albuminuria, which was in concordance
with most of the previous reports.
Based upon the concept that BP is an important risk
factor for microalbuminuria and macroalbuminuria, espe-
cially in diabetic patients, treatment of hypertension is
imperative in terms of reducing renal and cardiovascular
risks and should be executed as early as possible. Never-
theless, BP control is largely unsatisfactory in the general
population and is even lower in patients with diabetes and
CKD. The Hypertension and Diabetes Risk Screening and
Awareness study, which assessed the prevalence as well
as characteristics, comorbidities and management issues
of hypertension in 45125 primary care attendees in
Germany, demonstrated that BP control rates were only
18.7% [32]. The data from the US National Health and
Nutrition Examination Survey revealed that the rate of BP
control in hypertensive patients was also low, 29.2% in
1999–2000 and 36.8% in 2003–2004 [15]. In contrast, a
recent Korean Epidemiology Study on Hypertension
(KEY study) showed that BP was controlled in 51.0%
of hypertensive patients treated in primary care clinics
[16]. The reason for the divergence of the rates of BP
control may be due to the difference in the characteristics
of patients, such as the presence of diabetes and obesity,
and the ethnicity included in each study. On the other
hand, the BP control rates in diabetic patients are reported
considerably low in many studies. The Developing Edu-
cation on Microalbuminuria for Awareness of Renal
and Cardiovascular risk in Diabetes (DEMAND) study,
a cross-sectional clinic/medical center-based study on
T2DM patients in 33 countries, demonstrated that
81.0% had systolic BP 130 mmHg and/or diastolic BP
80 mmHg [26]. In addition, the results of the MAPS and
KEY study also revealed that BP was controlled only in
11.6% of Asian and 21.6% of Korean hypertensive T2DM
patients, respectively [16, 25]. These low control rates of
BP in diabetic patients is not surprising because the target
BP is lower and the response to antihypertensive medica-
tions is worse in diabetic versus nondiabetic patients [33].
In this study, however, the proportion of patients with
controlled BP (31.4%) was relatively higher compared
to those of the previous studies, which could be attributed
to the possibility that since the majority of primary care
physicians, who participated in the KEY study, was in-
vited to this KEY III study, they might treat hypertension
in diabetic patients more aggressively after the knowledge
of the results of KEY study.
Numerous studies have tried to identify the independent
risk factors for RI as well as micro- and/or macroalbumi-
nuria in primary care T2DM attendees with or without
hypertension. In summary advanced age [12, 25, 31], male
sex [25, 29, 31], high body mass index [25, 29], long
duration of diabetes [25, 26], the presence of diabetic com-
plications [12, 25, 26, 29], high systolic and diastolic BP
[12, 25, 26, 31], poor diabetes control [12, 26, 29], pres-
ence of RI [26, 29] and current smoking status [26] have
been reported as independent risk factors for micro- and/or
macroalbuminuria. In addition, one recent Japanese study
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found that age, the duration of diabetes, HbA1C, hyper-
lipidemia, smoking and the presence of microalbuminuria
were independently associated with RI in these patients
[29]. In agreement with a number of previous studies, we
also demonstrated that male sex, the duration of diabetes, the
presence of diabetic complications, systolic BP, HbA1C and
the presence of RI were independent risk factors for micro-/
macroalbuminuria, while advanced age, female sex, the du-
ration of diabetes, the presence of diabetic complications and
urinary ACR were independently associated with RI. These
findings support the well-known fact that strict BP and glu-
cose control are mandatory to prevent the development of
albuminuria even in hypertensive T2DM patients.
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